-
China establishes national standardized pain treatment center
Xinhua
October 27, 2023
China on Friday unveiled a national standardized pain treatment center in its capital city of Beijing.
-
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology
PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
-
InnoCare Pharma announced 2023 interim results as of 30 June 2023
PharmaSources
September 04, 2023
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
-
Vetter Earns Frost & Sullivan’s Customer Value Award for the Third Time
PharmaSources
August 30, 2023
On August 29, 2023,Vetter has been awarded the Frost & Sullivan’s 2023 Global Customer Value Leadership Award in the aseptic fill-and-finish market for the company’s high performance for its customers.
-
T-CURX GmbH Announces Appointment of Two Industry Leaders to its Board of Directors
PharmaSources
August 28, 2023
On August 28, 2023,T-CURX GmbH announces the appointments of Dr. Hans-Peter (HP) Gerber, PhD, as Chairman and of Dr. Bernd Eschgfäller, PhD, as an independent Board member.
-
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis
PharmaSources
August 28, 2023
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.
-
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
PharmaSources
August 18, 2023
Sartorius and Repligen Corporation launch integrated system with Biostat STR® and XCell® ATF for upstream process intensification.
-
Samanta Cimitan Appointed Chief Executive Officer (CEO) at Celonic
PharmaSources
August 03, 2023
On August 03, 2023,Celonic Group has appointed Dr. Samanta Cimitan as the Chief Executive Officer (CEO) of the Celonic Group, a subsidiary of the independent and privately owned J.RETTENMAIER & Söhne Company (JRS Group).
-
Coriolis Pharma and RheaVita Join Forces in Collaboration for Continuous and Controlled Freeze-Drying Technology
PharmaSources
July 31, 2023
Coriolis Pharma and RheaVita join forces in collaboration for continuous and controlled freeze-drying technology.
-
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
PharmaSources
July 27, 2023
InnoCare announces approval of clinical trial of pan-TRK inhibitor Zurletrectinib for the treatment of pediatric patients in China.